Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease
- PMID:25661282
- DOI: 10.1016/j.rmed.2014.12.010
Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease
Abstract
Objectives: There is a general concern that hypnotic medications in patients with respiratory disorders have the potential to decrease respiratory effort and blunt the arousal response to hypoxemia which may lead to sleep breathing disorders. We investigated whether suvorexant, an orexin receptor antagonist approved for treatment of insomnia at a maximum daily dose of 20 mg in the US, causes sleep breathing disorders in patients with chronic obstructive pulmonary disease (COPD).
Design: This was a randomized, double-blind, placebo-controlled, 2-period, cross-over, study performed in 9 sleep laboratories/clinical research units in the United States. The participants were 25 COPD patients aged 39-72 y with mild-to-moderate airflow limitation based on GOLD spirometry criteria. In each period, patients received suvorexant (40 mg in <65 y-olds; 30 mg in ≥65 y-olds) or placebo for four consecutive nights. Respiratory function during sleep was measured by oxygen saturation using pulse oximetry (SpO2, primary endpoint) and Apnea Hypopnea Index (AHI, secondary endpoint). The study was powered to rule out a difference between treatments of -2 percentage points in SpO2 on Day 4.
Results: There was no treatment effect following single and multiple doses of suvorexant on mean SpO2 during total sleep time (Day 1: suvorexant = 93.14%, placebo = 93.24%, difference = -0.10 [90% CI: -0.50, 0.31]; Day 4: suvorexant = 93.38%, placebo = 92.99%, difference = 0.39 [90% CI: -0.12, 0.91]). There was no clinically meaningful increase in mean AHI by suvorexant compared with placebo on Day 1 (difference = 0.72 [90% CI: -0.60, 2.04]) or Day 4 (difference = 2.05 [90% CI: 0.33, 3.77]).
Conclusions: These data do not suggest an overt respiratory depressant effect with 30-40 mg daily doses of suvorexant, up to twice the maximum recommended dose for treating insomnia in the US, in patients with mild-to-moderate COPD. Trial registration Clinicaltrials.gov identifier:NCT01293006.
Keywords: Chronic obstructive pulmonary disease; MK-4305; Orexin; Randomized trial; Respiration; Suvorexant.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
- Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD.Sun H, et al.J Clin Sleep Med. 2016 Jan;12(1):9-17. doi: 10.5664/jcsm.5382.J Clin Sleep Med. 2016.PMID:26194728Free PMC article.Clinical Trial.
- Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.Uemura N, McCrea J, Sun H, Donikyan M, Zammit G, Liu R, Louridas B, Marsilio S, Lines C, Troyer MD, Wagner J.Uemura N, et al.J Clin Pharmacol. 2015 Oct;55(10):1093-100. doi: 10.1002/jcph.523. Epub 2015 Jun 3.J Clin Pharmacol. 2015.PMID:25903940Clinical Trial.
- Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease.Boof ML, Dingemanse J, Brunke M, Esselmann A, Heymer P, Kestermann O, Lederer K, Fietze I, Ufer M.Boof ML, et al.J Sleep Res. 2021 Aug;30(4):e13248. doi: 10.1111/jsr.13248. Epub 2021 Jan 8.J Sleep Res. 2021.PMID:33417730Clinical Trial.
- Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.Owen RT.Owen RT.Drugs Today (Barc). 2016 Jan;52(1):29-40. doi: 10.1358/dot.2016.52.1.2439940.Drugs Today (Barc). 2016.PMID:26937493Review.
- Suvorexant (Belsomra) for insomnia.[No authors listed][No authors listed]Med Lett Drugs Ther. 2015 Mar 2;57(1463):29-31.Med Lett Drugs Ther. 2015.PMID:25719996Review.No abstract available.
Cited by
- Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations.Mogavero MP, Silvani A, Lanza G, DelRosso LM, Ferini-Strambi L, Ferri R.Mogavero MP, et al.Nat Sci Sleep. 2023 Jan 22;15:17-38. doi: 10.2147/NSS.S201994. eCollection 2023.Nat Sci Sleep. 2023.PMID:36713640Free PMC article.Review.
- Profile of suvorexant in the management of insomnia.Sutton EL.Sutton EL.Drug Des Devel Ther. 2015 Nov 11;9:6035-42. doi: 10.2147/DDDT.S73224. eCollection 2015.Drug Des Devel Ther. 2015.PMID:26648692Free PMC article.Review.
- Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.Sun Y, Tisdale RK, Kilduff TS.Sun Y, et al.Front Neurol Neurosci. 2021;45:22-37. doi: 10.1159/000514963. Epub 2021 May 28.Front Neurol Neurosci. 2021.PMID:34052813Free PMC article.Review.
- Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD.Sun H, et al.J Clin Sleep Med. 2016 Jan;12(1):9-17. doi: 10.5664/jcsm.5382.J Clin Sleep Med. 2016.PMID:26194728Free PMC article.Clinical Trial.
- The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System.Fragale JE, James MH, Avila JA, Spaeth AM, Aurora RN, Langleben D, Aston-Jones G.Fragale JE, et al.Front Neurol Neurosci. 2021;45:117-127. doi: 10.1159/000514965. Epub 2021 May 28.Front Neurol Neurosci. 2021.PMID:34052815Free PMC article.Review.
Publication types
MeSH terms
Substances
Associated data
Related information
LinkOut - more resources
Full Text Sources
Medical